ArticleThe Journal of surgical research2025
Association Between Smoking and Thromboelastography With Platelet Mapping Parameters in Peripheral Artery Disease Patients.
Article in The Journal of surgical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionPeripheral artery disease (PAD) and smoking are intricately linked, yet the association between tobacco and coagulation dynamics in PAD patients remains incompletely understood. This study aims to compare thromboelastography parameters between smokers and nonsmokers with PAD undergoing revascularization.
methodsIn this single-center, cross-sectional study, 174 PAD patients were stratified into three equal groups based on smoking status: nonsmokers (n = 58), former smokers (n = 58), and current smokers (n = 58). Comprehensive demographic data, medical history, and medication use were documented. Thromboelastography with platelet mapping was performed on all patients. Informed consent was obtained from all patients under institutional review board protocols 2022P001918 and 2022P002264. Statistical analysis included one-way analysis of variance for normally distributed variables, Kruskal-Wallis tests for non-normally distributed variables, and chi-square tests for categorical variables, with significance set at P < 0.05.
resultsSignificant differences in coagulation parameters were observed across smoking groups. Overall clot strength (citrated rapid thromboelastography maximum amplitude) progressively decreased from nonsmokers (67.90 mm) to former smokers (64.80 mm) to current smokers (62.50 mm) (P < 0.001). Fibrinogen contribution to clot formation (calculated functional fibrinogen maximum amplitude) showed similar decline (31.50 mm, 24.00 mm, 21.50 mm, respectively, P = 0.007). Clot formation kinetics (citrated kaolin kinetics time) was prolonged in current smokers (1.35 min) and former smokers (1.30 min) compared to nonsmokers (1.00 min) (P = 0.045). Notably, arachidonic acid-mediated platelet function was significantly impaired in current smokers, with increased arachidonic acid -pathway inhibition (66.5% versus 52.1% versus 25.3%, P = 0.043).
conclusionsSmoking is significantly associated with altered coagulation profiles in PAD patients, with implications for bleeding risk assessment and personalized antithrombotic therapy selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.